The membership fee is charged regardless of whether you're actively receiving medication
In SUSTAIN 3, 34% of patients achieved target with once-weekly semaglutide 1.0 mg, compared with 13% for exenatide ER, while in SUSTAIN 7, 33% and 48% achieved target with once-weekly semaglutide 0.5 mg and 1.0 mg, respectively, compared with 16% with dulaglutide 0.75 mg and 23% with dulaglutide 1.5 mg (Table 1)
In many diabetes cardiovascular outcome trials, average weight loss was relatively modest, yet the reduction in cardiovascular events was meaningful, suggesting additional biology at play beyond lighter body, healthier heart. 2) The timeline doesnt always match weight loss explains it all. Weight loss is a gradual process, but cardiovascular risk reduction can begin earlier than youd expect if weight loss were the only driver
doi: 10.1517/17460441.2014.886562 45 Jalili-FiroozinezhadSMirandaCCCabralJMS